Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 2/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.53 |
| ▸ | TACR2 | P21452 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SHBG | P04278 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.53 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13798097 | 0.98 | FAAH (0.57) | TAAR1FAAHESR1ADRA2AADORA3 | |
| SCHEMBL2615716 | 0.98 | FAAH (0.57) | TAAR1FAAHESR1ADRA2AADORA3 | |
| SCHEMBL9352104 | 0.98 | TAAR1 (0.53) | TAAR1FAAHESR1ADRA2AADORA3 | |
| SCHEMBL2093367 | 0.98 | FAAH (0.57) | TAAR1FAAHESR1ADRA2AADORA3 | |
| SCHEMBL924516 | 0.98 | FAAH (0.57) | TAAR1FAAHESR1ADRA2AADORA3 | |
| SCHEMBL9349090 | 0.96 | FAAH (0.56) | TAAR1FAAHESR1ADRA2AADORA3 | |
| SCHEMBL9349203 | 0.96 | FAAH (0.56) | TAAR1FAAHESR1ADRA2AADORA3 | |
| SCHEMBL9347785 | 0.96 | FAAH (0.56) | TAAR1FAAHESR1ADRA2AADORA3 | |
| SCHEMBL17108417 | 0.94 | MAOB (0.58) | TAAR1FAAHESR1ADRA2AADORA3 | |
| SCHEMBL10382748 | 0.94 | MAOB (0.58) | TAAR1FAAHESR1ADRA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103384661-B | Mineralocorticoid receptor antagonists | 默沙东公司 | 2016-08-10 | — | — | CN | claimed |
| US-11584852-B2 | Compound and colored resin composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-02-21 | — | — | US | disclosed |
| US-20210002487-A1 | COMPOUND AND COLORED RESIN COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-01-07 | — | — | US | disclosed |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| WO-2019163732-A1 | COMPOUND AND COLORING RESIN COMPOSITION | 住友化学株式会社 | 2019-08-29 | — | — | WO | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
| CN-107922830-A | Electrochromic compounds and the optical article containing them | 依视路国际公司 | 2018-04-17 | — | — | CN | disclosed |
| CN-107760174-A | A kind of hydrophobic type weather-resistant powder paint and preparation method thereof | 浙江捷宇新材料科技股份有限公司 | 2018-03-06 | — | — | CN | disclosed |
| EP-2981518-A2 | \"AN IMPROVED PROCESS FOR THE PREPARATION OF FLUVOXAMINE MALEATE\ | ZCL Chemicals Ltd. (IN) | 2016-02-10 | — | — | EP | disclosed |
| WO-2014178064-A2 | \"AN IMPROVED PROCESS FOR THE PREPARATION OF FLUVOXAMINE MALEATE\ | ZCL CHEMICALS LIMITED (IN) | 2014-11-06 | — | — | WO | disclosed |
| WO-2008128062-A1 | GLYCOLIPIDS AND ANALOGUES THEREOF AS ANTIGENS FOR NK T CELLS | THE ROCKEFELLER UNIVERSITY (US) | 2008-10-23 | — | — | WO | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1847533-A1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070238871-A1 | Glycolipids And Analogues Thereof As Antigens For NKT Cells | THE ROCKEFELLER UNIVERSITY (US) | 2007-10-11 | — | — | US | disclosed |
| US-20070238871-A1 | Glycolipids And Analogues Thereof As Antigens For NKT Cells | THE ROCKEFELLER UNIVERSITY (US) | 2007-10-11 | — | — | US | disclosed |
| CN-1950337-A | (4, 5,6, 7-tetrahydro-1-H-indol-7-yl) acetic acid derivatives for the treatment of Alzheimer's disease | MERCK SHARP & DOHME (GB) | 2007-04-18 | — | — | CN | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| CN-1524071-A | Malononitrile compounds and their use as pesticides | ס�ѻ�ѧ��ҵ��ʽ���� | 2004-08-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | TAAR1 163/4885FAAH 3448/4885ESR1 1871/4885 |
| US-11584852-B2 | Compound and colored resin composition | H1-0, HRH3, HRH4 | TAAR1 1486/4885FAAH 1740/4885ESR1 1650/4885 |
| US-20210002487-A1 | COMPOUND AND COLORED RESIN COMPOSITION | H1-0, HRH3, HRH4 | TAAR1 1486/4885FAAH 1740/4885ESR1 1650/4885 |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, FXR1, SLC10A1 | TAAR1 748/4885FAAH 1553/4885ESR1 1837/4885 |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | TAAR1 748/4885FAAH 1553/4885ESR1 1837/4885 |
| US-20070238871-A1 | Glycolipids And Analogues Thereof As Antigens For NKT Cells | CD69, KLRK1, PBK | TAAR1 2104/4885FAAH 1204/4885ESR1 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.